Becton, Dickinson and Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDX research report →
Range $165 – $242
Price Chart
About the company
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world.
- CEO
- Thomas E. Polen Jr.
- IPO
- 1973
- Employees
- 60,000
- HQ
- Franklin Lakes, NJ, US
Get TickerSpark's AI analysis on BDX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $57.96B
- P/E
- 51.25
- Fwd P/E
- 16.05
- PEG
- -1.77
- P/S
- 2.86
- P/B
- 2.35
- EV/EBITDA
- 15.68
- Div Yield
- 1.87%
- Gross Margin
- 47.34%
- Op Margin
- 11.58%
- Net Margin
- 5.66%
- ROE
- 4.65%
- ROIC
- 4.18%
Latest fiscal year · YoY change
- Revenue
- $19.46B-10.9%
- Gross Profit
- $9.21B-7.2%
- Op Income
- $2.26B
- Net Income
- $1.15B-31.7%
- EPS
- $4.11-29.6%
- OCF Growth
- -1.9%
- FCF Growth
- +0.9%
- 52W High
- $220.36
- 52W Low
- $140.11
- 50D MA
- $193.75
- 200D MA
- $169.57
- Beta
- 0.28
- RSI (14)
- 63
- Avg Volume
- 1.81M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BD reported a strong fiscal Q4 and full-year 2026, with broad-based growth, margin expansion in the quarter, and FY 2027 guidance for low-single-digit revenue growth and roughly flat operating margins as Alaris headwinds roll off later.· November 5, 2026
- Q4 revenue was $5.3 billion, up 5.6%, and adjusted EPS was $4.15, up 27.3%; full-year revenue was $19.5 billion, up 3.9%, with adjusted EPS of $12.70, up 6.7%.
- Growth was broad-based, with double-digit gains in several key platforms including Advanced Patient Monitoring, PureWick, advanced tissue regeneration, biologic drug delivery, and Rowa pharmacy automation.
- FY 2027 guide calls for low-single-digit revenue growth, adjusted EPS of $13.10 to $13.30, roughly flat operating margins, and Q1 revenue at the low end of the range.
- Management said the U.S. government partnership does not add to current guidance because Section 232 tariff scope/timing is not finalized, though any future tariff relief would be upside.
- Free cash flow improved sharply to $2.9 billion, up 42%, and BD returned $3.6 billion to shareholders in FY 2026 while ending at 2.7x net leverage.
BD reported Q4 fiscal 2026 revenue of $5.3 billion, up 5.6%, and adjusted EPS of $4.15, up 27.3%. For the full year, revenue was $19.5 billion, up 3.9%, and adjusted EPS was $12.70, up 6.7%. Q4 adjusted gross margin was 56.8% and adjusted operating margin was 28.6%, up 180 and 280 basis points, respectively, versus the prior year; full-year adjusted gross margin was 55.1% and adjusted operating margin was 25.0%, down 10 and 20 basis points, respectively, versus the prior year. FY 2027 guidance is for low-single-digit revenue growth, about 70 basis points of FX headwind based on current spot rates, adjusted EPS of $13.10 to $13.30, an adjusted tax rate of 16% to 17%, weighted average shares of about 273 million, and roughly flat operating margins year over year. Q1 FY 2027 revenue is expected at the low end of the full-year range, with Q1 adjusted EPS of $2.32 to $2.37.
Tom Polen framed FY 2026 as a milestone year because BD completed the separation of its life sciences business and is now a more focused medtech company. He emphasized that the company’s growth platforms are gaining momentum, aided by commercial investments, innovation, and BD Excellence, and said the portfolio is showing the growth and earnings potential of “New BD.” His tone was confident and constructive, with repeated references to strong execution, a robust pipeline, and a path to sustainable mid-single-digit growth.
Vitor Roque focused on the quarter’s financial strength, highlighting Q4 adjusted gross margin of 56.8%, adjusted operating margin of 28.6%, and adjusted EPS of $4.15, all above expectations. For the year, he cited free cash flow of $2.9 billion, up 42%, free cash flow conversion rising from about 57% to 74% including separation costs, and $3.6 billion returned to shareholders, including about $2.4 billion of share repurchases and $1.2 billion of dividends; BD also paid down $2.4 billion of debt and ended at 2.7x net leverage. He said FY 2027 margins are expected to be roughly flat because tariff and inflation pressures are being offset by BD Excellence, mix, and pricing, and he reaffirmed capital allocation priorities of buybacks, debt paydown, and tuck-in M&A.
Analysts focused on how much of growth is being driven by deliberate investment, why FY 2027 revenue guidance looks conservative after a strong back half, and how the company is thinking about tariffs, capital allocation, and long-term margin expansion. Management said the guide is prudent, with Q1 pressured more by Alaris and an APM systems cutover, while underlying demand remains strong. On tariffs, BD said its current guide assumes tariffs generally in line with FY 2026 and does not include any benefit from the U.S. government agreement because the final Section 232 scope and timing are not yet known; any relief would be upside. Questions also covered AI, where management pointed to Incada AI, APM algorithms, and internal AI deployment in manufacturing, sales, and R&D as potential growth and efficiency drivers.
The call showed broad operational momentum, with multiple growth platforms posting strong gains and management saying the key investments in sales, R&D, and manufacturing are translating into share gains and accretive margins. Free cash flow, shareholder returns, and leverage all improved, while management sees a path to continued earnings expansion and eventually a return to mid-single-digit growth once the Alaris headwind rolls off.
FY 2027 guidance is still only low-single-digit revenue growth and flat operating margins, which implies management is absorbing Alaris headwinds, a tariff/inflation environment, and an APM systems transition. The government/tariff deal is not in the guide yet, so the expected benefit is uncertain and dependent on final Section 232 details and implementation. Management also acknowledged that some growth is being supported by continued investment, which could keep margins from expanding near term.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 272.39M
- Float Shares
- 271.83M
of shares held by institutions
1,478 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BDX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Thomas KeanHouse · NJ07 | Sell | May 21, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Mar 17, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jun 24, 25 | Filing → |
| Thomas KeanHouse · NJ07 | Buy | May 13, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | May 15, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Apr 8, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | Mar 5, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 9, 24 | Filing → |
| John JamesHouse · MI10 | Sell | Sep 4, 24 | Filing → |
| John JamesHouse · MI10 | Buy | Nov 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 36.68M | ▲ 4.22M |
| Blackrock, Inc. | 23.62M | ▼ 974.59K |
| Vanguard Capital Management LLC | 17.82M | ▼ 167.63K |
| State Street Corp | 15.21M | ▲ 208.81K |
| Vanguard Portfolio Management LLC | 14.70M | ▼ 276.48K |
| First Eagle Investment Management, LLC | 13.88M | ▲ 68.35K |
| Invesco Ltd. | 8.87M | ▼ 26.67K |
| Geode Capital Management, LLC | 8.09M | ▼ 52.65K |
| Massachusetts Financial Services Co | 7.76M | ▼ 891.33K |
| Franklin Templeton Inc | 7.65M | ▲ 643.10K |
| Greenhaven Associates Inc | 5.90M | ▲ 223.02K |
| Wellington Management Group Llp | 5.58M | ▼ 774.97K |
Held by 1,830 ETFs
Biggest fund positions in BDX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Huffines Robert Luther | other | 158 |
| Nov 6, 26 | Byington Carrie L | other | 79 |
| Nov 5, 26 | Polen Thomas E Jr | other | 20,239 |
| Nov 5, 26 | Polen Thomas E Jr | sell | 17,246 |
| Nov 5, 26 | Polen Thomas E Jr | sell | 2,993 |
| Nov 5, 26 | Polen Thomas E Jr | other | 20,239 |
| Oct 26, 26 | Feld Michael | sell | 76 |
| Sep 28, 26 | Feld Michael | sell | 76 |
| Sep 2, 26 | Roque Vitor | other | 190 |
| Aug 26, 26 | Feld Michael | sell | 165 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BDX coverage
Recent articles, reports, and earnings notes.

Top Healthcare Dividend Stocks: Our 5 Picks for November 2026
Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.

Davion Healthcare Prices Nasdaq Direct Listing on Home Testing Push
Davion Healthcare Plc is set to list on Nasdaq on 2026-10-22, with a price range not disclosed and a market cap of $252,750,000. The company is coming public as a direct listing, so there is no traditional underwritten IPO bookbuild or IPO proceeds. The bull case is a pre-revenue medtech story with multiple registered products and a consumer OTC model. The bear case is that the stock starts trading without the cushion of an IPO raise, while cash remains extremely thin and execution risk is high.

What to Watch as DRC Medicine's SPAC Merger Heads to Close
DRC Medicine is a Tokyo-based healthcare and biotech company going public via a merger with Ribbon Acquisition Corp. (NASDAQ: RIBB). The setup offers a development-stage story with real upside if its mask, diagnostics, and certification pipeline advances, but shareholders should watch redemption risk and dilution closely.
Want a deeper read on BDX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
BD Marks 85 Years of Essential Medical Device Manufacturing in Glen Falls, NY
prnewswire.com · Nov 19
BD Named to TIME's 2027 List of America's Top Manufacturers
prnewswire.com · Nov 19
These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys
fool.com · Nov 16
Nike Among 13 Dividend Growth Companies To Announce Annual Dividend Increases In Latter Half Of November
seekingalpha.com · Nov 16
Brown Advisory Large-Cap Sustainable Value Strategy Q3 2026 Portfolio Review
seekingalpha.com · Nov 13
BD to Host Investor Day on December 10, 2026
prnewswire.com · Nov 10
Dividend Announcements: October 31-November 6, 2026 (Part 1 Of 2)
seekingalpha.com · Nov 8
3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years
247wallst.com · Nov 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.